Compile Data Set for Download or QSAR
Report error Found 7 Enz. Inhib. hit(s) with all data for entry = 11569
TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627520(US20230331734, Example 5)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627523(US20230331734, Example 26)
Affinity DataIC50: 100nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627517(US20230331734, Example 1)
Affinity DataIC50: 550nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627518(US20230331734, Example 2)
Affinity DataIC50: 550nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627519(US20230331734, Example 3)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627521(US20230331734, Example 6)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent

TargetReplicase polyprotein 1a(2019-nCoV)
Enanta Pharmaceuticals

US Patent
LigandPNGBDBM627522(US20230331734, Example 25)
Affinity DataIC50: 1.00E+3nMAssay Description:Recombinant SARS-CoV-2 3CL-protease was expressed and purified. TAMIRA-SITSAVLQSGFRKMK-Dabcyl-OH peptide 3CLpro substrate was synthesized. Black, low...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/1/2023
Entry Details
Go to US Patent